Senseonics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2016 and Full Year 2017
January 05, 2017 at 10:15 pm
Share
Senseonics Holdings, Inc. provided revenue guidance for the fourth quarter and full year 2016 and full year 2017. For the quarter, the company expects revenue to be approximately $0.3 million for fourth quarter 2016.
For the year, the company expects revenue to be $0.3 million
The company projects revenue for full year 2017 to be in the range of $6.0 million to $7.0 million.
Senseonics Holdings, Inc. is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the diabetes community. Its glucose monitoring (CGM) systems, Eversense, Eversense XL, and Eversense E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user's smartphone. Eversense consists of three primary components: a small sensor inserted subcutaneously under the skin by a healthcare provider; an external removable smart transmitter that receives, assesses and relays data from the sensor and provides vibratory alerts; and a mobile app that receives data from the transmitter and provides real-time glucose readings, alerts and other data the person's mobile device. Its CGM system continually and accurately measures a person's glucose levels for up to six months.
SENSEONICS HOLDINGS, INC. 
